A recent poster presentation at Psych Congress Elevate by Johnson & Johnson has placed esketamine nasal spray, marketed as Spravato,…
Read More
J&J Positions Spravato Remission Data at Forefront of Treatment-Resistant Depression Growth Strategy
Johnson & Johnson (J&J) is intensifying its marketing efforts for Spravato (esketamine) by spotlighting compelling remission rate data for treatment-resistant…
Read More
J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push
More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis in 1962 while diligently searching for a safer…
Read More
J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push
More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis in a quest for a safer anesthetic, the…
Read More
J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push
Johnson & Johnson is intensifying its efforts to expand the market footprint of Spravato (esketamine) for treatment-resistant depression (TRD), leveraging…
Read More
J&J Poster Puts Spravato Remission Data at Center of Treatment-Resistant Depression Growth Push
More than six decades after Calvin Stevens first synthesized ketamine at Parke-Davis while searching for a safer anesthetic, the molecule…
Read More
How breast cancer cells survive in bone marrow after remission
The Challenge of Estrogen Receptor-Positive Breast Cancer Estrogen receptor-positive (ER+) breast cancer represents approximately 70% to 80% of all breast…
Read More
How breast cancer cells survive in bone marrow after remission
The Hidden Threat of Estrogen Receptor-Positive Breast Cancer Estrogen receptor-positive (ER+) breast cancer is the most prevalent form of the…
Read More
How breast cancer cells survive in bone marrow after remission
The study, published in the Journal of Clinical Investigation, identifies a sophisticated "smuggling" operation between cancer cells and the bone…
Read More
